With a series of recent collaborations in hand, the company is leveraging its experience in autoimmune biomarkers to move into the immunoncology space.
Under the collaboration, they will use Protagen's SeroTag platform to test cancer immunotherapy patients for markers linked to immune-related adverse events.
The partners will use Protagen’s autoantibody measuring technology to identify biomarkers of patient response to cancer immunotherapies.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The company has partnered with the German National Center for Tumor Diseases to identify biomarkers for predicting response to immunotherapy in melanoma patients.
The license allows Inova to include the BICD2 biomarker in its portfolio of connective tissue disease reagents aimed at the diagnosis of systemic sclerosis.
The company now offers three CE-marked autoantibody assays — for BICD2, Scl70, and CENP-B — that can be used for clinical management of the condition.
According to the company, some of the autoantibodies it has identified as disease markers appear to be directed against potentially interesting drug targets.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
The company hopes to identify a subset of predictive markers from a current panel of 100 proteins it identified as possibly useful through previous RA studies.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.